Search EDIT
Editas Medicine, Inc.
Nasdaq · CIK 1650664
Last close2.62
Daily change+0.10 (3.97%)
10 Years gain-80.58%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
EDIT · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
60.9Momentum
100.0Acceleration
100.0Confidence
77.0Annual Revenue10
Quarterly Revenue35
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth24.5 / 25
Quality16.4 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 3946.0289 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 43.6332%.
Key Metrics
Revenue Growth TTM305.87%OK
Revenue CAGR 3Y27.15%OK
Gross Margin100%OK
Operating Margin-463%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y1,304.24%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y43.63%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $40.52M | $40.52M | -$160.01M | -$165.24M | -$165.85M | 100% | -394.89% | -409.3% | n/a | 88.75M |
| 2025 FY Dec 31, 2024 | $32.31M | $32.31M | -$251.15M | -$210.28M | -$219.11M | 100% | -777.22% | -678.07% | n/a | 82.34M |
| 2024 FY Dec 31, 2023 | $78.12M | $78.12M | -$169.18M | -$132.18M | -$136.90M | 100% | -216.56% | -175.23% | -630.56% | 75.97M |
| 2024 FY Dec 31, 2022 | $19.71M | $19.71M | -$225.95M | -$177.35M | -$181.47M | 100% | -1,146.26% | -920.59% | -508.53% | 68.66M |
| 2023 FY Dec 31, 2021 | $25.54M | $25.54M | -$193.15M | -$163.80M | -$171.78M | 100% | -756.13% | -672.49% | -674.07% | 67.62M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $25.84M | sum latest 4 fiscal quarters Revenue | OK | 0001650664-26-000083, 0001650664-25-000156 |
| Revenue Growth TTM | 305.87% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001650664-26-000083, 0001650664-25-000156 |
| Revenue CAGR 3Y | 27.15% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001650664-26-000017 |
| Revenue CAGR 5Y | -14.89% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001650664-26-000017 |
| Gross Profit CAGR 3Y | 27.15% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001650664-26-000017 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001650664-26-000083, 0001650664-25-000156 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001650664-26-000083, 0001650664-25-000156 |
| Operating Margin | -463% | Operating Income / Revenue | OK | 0001650664-26-000083, 0001650664-25-000156 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001650664-26-000083 |
| Current Ratio | 3.19x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 3.8x | (Cash + Short-term Investments) / Total Debt | OK | 0001650664-26-000083 |
| Revenue per Diluted Share | $0.22 | Revenue / Diluted Shares | OK | 0001650664-26-000083, 0001650664-25-000156 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |